Intellia Therapeutics, Inc. (NASDAQ:NTLA) has released positive new clinical data from the ongoing phase 1 trial of Nexiguran Ziclumeran (Nex-Z), also known as NTLA-2001, in patients with ...

Phase 1 data indicate Intellia’s medicine could be a powerful treatment for a cardiac form of ATTR amyloidosis. But rival drugs are further ahead.

Chardan raised the firm’s price target on Intellia Therapeutics (NTLA) to $91 from $88 and keeps a Buy rating on the shares. The company ...

Intellia Therapeutics ( (NTLA) ) just unveiled an announcement.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top ...

Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in ...

In today's biotech news, Zepbound trial data, Regenxbio's Duchenne muscular dystrophy treatment, and Intellia's promising ...

The Cystic Fibrosis Foundation has agreed to invest up to $15 million in ReCode Therapeutics to support their gene editing collaboration with Intellia Therapeutics. The funding is intended to be used ...

Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...

But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...

In recent trading, Intellia Therapeutics Inc (NTLA) stock price has shown some volatility, fluctuating -16.50% over the last five trades and -33.41% over the past 30 trades. This represents a notable ...

Intellia Therapeutics CEO John Leonard has, for the last couple years, found himself stuck in a financial Groundhog Day.

On Wednesday, Intellia Therapeutics Inc (NTLA) stock saw a decline, ending the day at $16.11 which represents a decrease of $-0.54 or -3.24% from the prior close of $16.65. The stock opened at $16.8 ...